Wrinkle Reducer (Neuromodulator / Botox)

Neuromodulator injections — including Botox and other FDA-approved brands — to relax targeted facial muscles and reduce dynamic wrinkles including forehead lines, frown lines, crow's feet, and bunny lines. JECT's team of PA-Cs and NP-Cs, supervised by Medical Director Ali Vafa MD, administers treatments designed to achieve natural-looking results. Common treatment areas include the upper face, perioral region, and masseter for jawline slimming. Sessions are typically brief and may support results lasting three to four months.

JECT NYC offers wrinkle reducer injections using FDA-approved neuromodulators as a cornerstone aesthetic treatment at its West Village flagship. The injections are performed by a team of PA-Certified and Nurse Practitioner-Certified providers, all supervised by Medical Director Ali Vafa MD MPH — a practitioner holding Diamond status with Allergan (the maker of Botox), Chairman-level certification with Galderma (Dysport, Sculptra), and Black Premier status with Merz (Xeomin, Radiesse). This level of injector experience represents the top tier of pharmaceutical partnership programs in the aesthetics industry. The neuromodulator is injected in precise microdosing quantities into targeted facial muscles, temporarily interrupting the neuromuscular signal that causes the muscle to contract fully. Over the following seven to fourteen days, the overlying skin smooths as the mechanical cause of the dynamic wrinkle is removed. Common treatment zones at JECT include the glabella (frown lines), forehead, lateral canthal area (crow's feet), bunny lines across the nasal bridge, and the perioral lines around the mouth. Masseter injections for jawline slimming and gummy smile correction are also offered. JECT's ToxBooster proprietary protocol pairs a wrinkle reducer with a complementary chemical peel in a combined treatment for enhanced skin texture improvement alongside muscle relaxation. A 9-area package is available at $2,310 (valued at $2,475), and member pricing of approximately 10% below standard rates applies to JECT membership holders. Results are typically associated with onset within three to seven days and duration of three to four months, after which repeat treatment may be considered.